Detectability of the Bladder With an Early Prototype of the Bladder Sensor

Essity

Status

Completed

Conditions

Urinary Incontinence

Treatments

Device: TENA-PROTO1

Study type

Interventional

Funder types

Industry

Identifiers

NCT04720222

ELECTRO

P2101 (Other Identifier)

NL76062.028.20 (Other Identifier)

Details and patient eligibility

About

This is an explorative, monocentric, feasibility study to evaluate the detectability of the bladder in healthy subjects by ultrasound monitoring with the early prototype of a future bladder sensor, which is intended for use for an individual suffering from urinary incontinence.

Full description

The purpose of this clinical investigation with healthy subjects (defined as subjects without urological problems or lower urinary tract symptoms, assured by pre-defined inclusion and exclusion criteria) is to collect raw measurement data of the urinary bladder region of volunteers with the TENA-PROTO1, in multiple postural positions to evaluate the detectability of the bladder in the intended users and to determine the position criteria for the (future) ultrasound sensor on the lower abdomen. Secondarily, this clinical investigation aims to collect data on the adhesive and supportive belt used to fix the transducer assembly to the lower abdomen by the subject. Furthermore, safety of the subjects will be continously documented such as adverse events (AE) and device deficiencies (DD); AEs, Adverse Device Events (ADE), Severe Adverse Events (SAE), Severe Adverse Device effects (SADE), Unanticipated Serious Adverse Device Effects (USADE) and DDs.

Enrollment

91 patients

Sex

All

Ages

35 to 74 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Men, women and diverse ≥ 35 and <75 years old
Capability to understand the subject information and to provide conscious informed consent
Signed informed consent for study participation and data protection regulations
All subjects with childbearing potential must either be surgically sterile (hysterectomy or tubal ligation) or agree to use a reliable method of contraception with a failure rate of a Pearl-Index less than 1% per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra uterine devices, sexual abstinence or vasectomized partner for at least 4 weeks
Willingness to conduct a urine pregnancy test for all subjects with childbearing potential
BMI ≥18.5 kg/m² and <40 kg/m²
Capability and willingness to follow the following requirements: protocol, current hygiene concept and laboratory safety

Exclusion criteria

Subjects with urological problems or lower urinary tract symptoms
Subjects with breached skin, open wounds, sutures or major scar tissue in the suprapubic region.
Subjects with active implants that can be affected by electromagnetic interference (e.g. pacemaker)
Subjects with symptoms of constipation or diarrhea
Subjects who are pregnant or breast feeding
Known allergies or intolerances to one or several components of the study product
Alcohol abuse as reported by subject and/ or suspected by investigator that impacts capability to understand the subject information and to provide conscious informed consent in the discretion of the investigator / study personnel
Drug abuse as reported by subject and/ or suspected by investigator that impacts capability to understand the subject information and to provide conscious informed consent in the discretion of the investigator / study personnel
Objections of the investigator to the subject's participation in the trial due to medical reasons or any other reason for which the subject should not participate in the opinion of the investigator
Participation in any clinical investigation with systemic and/or pharmaceutical substances within the last 4 weeks and/or in parallel
Sponsors, manufacturers or CRO staff